Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute, discusses the challenges with finding biomarkers for immunotherapy agents.
Skin Cancer Awareness Month: Sun Safety and Tackling Diagnosis
For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.
Read More
Navigating the Landscape of Immunotherapy Toxicities
Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.
Listen
Advancing Care in Urothelial Carcinoma With the MAIN-CAV Trial
In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.
Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy
In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.
Exploring the Frailty Factor in Stem Cell Transplant Hospitalization
In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.
FDA to Consider Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer
If approved, zenocutuzumab would be the first targeted therapy for neuregulin 1 fusion-positive lung and pancreatic cancers.